All In Biotech

Drug Trial Radar · NCT07020117

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Aug 22, 2025

Primary completion

Dec 2027

Study completion Jun 2032

Sponsor

Lead sponsor
Aktis Oncology, Inc.Industry
Sponsor type
Industry
First posted
Jun 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.

Conditions

  • Urothelial Carcinoma Bladder
  • Triple Negative Breast Cancer (TNBC)
  • Hormone Receptor Positive Breast Adenocarcinoma
  • Non Small Cell Lung Cancer
  • Cervical Adenocarcinoma
  • Colorectal Adenocarcinoma
  • Head and Neck Cancer

Interventions

  • [225Ac]Ac-AKY-1189 (therapeutic)Drug

    \[225Ac\]Ac-AKY-1189 Injection

  • [64Cu]Cu-AKY-1189 (imaging)Drug

    \[64Cu\]Cu-AKY-1189 Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Patients with Dose-Limiting ToxicitiesTime frame: From enrollment to the end of Cycle 1 (each cycle is 28 days)
  2. Part 1: Occurence of Adverse Events by SeverityTime frame: Up to the End of Treatment (30 days after the last dose)
  3. Part 2: Objective Response Rate (ORR)Time frame: Up to 30 days following last administration

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • Hoag Memorial Hospital Presbyterian

    Irvine, California · Recruiting

  • Biogenix Molecular, LLC

    Miami, Florida · Withdrawn

  • Advent Health Medical Group Radiation Oncology at Central Florida

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • University of Kansas

    Westwood, Kansas · Recruiting

  • United Theranostics

    Glen Burnie, Maryland · Recruiting

  • BAMF Health

    Grand Rapids, Michigan · Recruiting

  • Icahn School of Medicine at Mt. Sinai

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • UPMC

    Pittsburgh, Pennsylvania · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.